Mink Therapeutics, Inc. ( (INKT) ) has released its Q3 earnings. Here is a breakdown of the information Mink Therapeutics, Inc. presented to its investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of allogeneic invariant natural killer T (iNKT) cell therapies aimed at restoring immune balance to treat cancer and immune disorders.
In its latest earnings report, MiNK Therapeutics highlighted significant advancements in its iNKT platform, showcasing durable clinical responses in refractory cancers and expanding its research into pulmonary diseases and transplantation. The company also announced strategic leadership additions to further its development goals.
Key financial metrics revealed a net loss of $2.9 million for Q3 2025, compared to $1.8 million in the same quarter of 2024, reflecting ongoing investment in its lead asset, agenT-797. The company ended the quarter with $14.3 million in cash, extending its financial runway through 2026. MiNK also launched a federally and philanthropically funded trial in collaboration with the University of Wisconsin to explore the use of agenT-797 in preventing graft-versus-host disease (GvHD).
The company continues to gain momentum with its iNKT platform, as evidenced by peer-reviewed publications validating its therapeutic potential across multiple high-need conditions. The addition of experts in pulmonary medicine and trauma to its leadership team is expected to drive pivotal development in these areas.
Looking ahead, MiNK Therapeutics is poised for multiple clinical and strategic milestones, with plans to initiate new trials and provide updates on its ongoing programs. The company remains focused on advancing its iNKT therapies to address unmet needs in oncology, transplantation, and severe inflammation.